Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer

被引：0
|
作者：
Ma, F. [1 ]
Qiu, F. [2 ]
Tong, Z. [3 ]
Wang, J. [4 ]
Shi, Y. [5 ]
Zhang, Y. [2 ,10 ]
Yu, G. [6 ]
Shi, H. [7 ]
Wu, X. [8 ]
Liu, A. [9 ]
Zhang, Y. [2 ,10 ]
Wang, H. [11 ]
Cheng, Y. [12 ]
Yang, H. [13 ]
Li, H. [14 ]
Chang, J. [15 ]
Xing, X. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[3] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc Pathol, Tianjin, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Med Oncol, Beijing, Peoples R China
[5] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Med Oncol Dept Breast Canc, Tianjin, Peoples R China
[6] Weifang Peoples Hosp, Med Oncol, Weifang, Peoples R China
[7] Gannan Med Univ, Affiliated Hosp 1, Med Oncol, Ganzhou, Peoples R China
[8] Hubei Canc Hosp, Mammary Ctr, Wuhan, Peoples R China
[9] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[10] Beijing Hosp, Med Oncol, Beijing, Peoples R China
[11] Nanchang Med Coll, Nanchang Peoples Hosp, Breast Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
[13] Hebei Univ, Affiliated Hosp, Med Oncol, Baoding, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Breast Med, Beijing, Peoples R China
[15] Guizhou Med Univ, Affiliated Hosp, Breast Oncol Dept, Guiyang, Guizhou, Peoples R China
[16] Shanghai Escugen Biotechnol Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349MO
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [1] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
    Wang, Jiani
    Tong, Zhongsheng
    Tan, Yinuo
    Shi, Yehui
    Wu, Yun
    Zhou, Qing
    Xing, Xiaoyan
    Chen, Xiaomei
    Qiu, Fuming
    Ma, Fei
    CELL REPORTS MEDICINE, 2024, 5 (09)
  • [2] ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
    Ma, F.
    Qiu, F.
    Tong, Z.
    Wang, J.
    Shi, Y.
    Li, L.
    Yu, G.
    Shi, H.
    Wu, X.
    Liu, A.
    Zhang, Y.
    Wang, H.
    Cheng, Y.
    Yang, H.
    Li, H.
    Chang, J.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S359 - S359
  • [3] Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer
    Zhao, Jing
    Huang, Fengbo
    Xu, Xia
    Zhang, Yan
    Xing, Xiaoyan
    Huang, Jian
    Qiu, Fuming
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [4] ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).
    Ma, Fei
    Qiu, Fuming
    Tong, Zhongsheng
    Shi, Yehui
    Yu, Guohua
    Wu, Xinhong
    Wang, Hong
    Wang, Jiani
    Yang, Hua
    Liu, Anwen
    Zhang, Yan
    Zheng, Hongmei
    Lan, Qiongyu
    Zhang, Yongqiang
    Cheng, Ying
    Zhou, Qing
    Xing, Xiaoyan
    Chen, Xiaomei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/ metastatic solid tumors
    Ma, Fei
    Qiu, Fuming
    Tong, Zhongsheng
    Wang, Jiani
    Tan, Yinuo
    Bai, Rui
    Zhou, Qing
    Xing, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer
    Ko, Andrew H.
    Coveler, Andrew L.
    Schlechter, Benjamin L.
    Bekaii-Saab, Tanios
    Wolpin, Brian M.
    Clark, Jeffrey W.
    Bockorny, Bruno
    Bai, Li-Yuan
    Lin, Yu-Chin
    Chiang, Evelyn
    Langecker, Peter
    Lin, Shih-Yao
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 221 - 228
  • [7] Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study
    Abelman, Rachel Occhiogrosso
    Spring, Laura
    Fell, Geoffrey G.
    Ryan, Phoebe
    Vidula, Neelima
    Medford, Arielle J.
    Shin, Jennifer
    Isakoff, Steven J.
    Moy, Beverly
    Ellisen, Leif W.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
    Meric-Bernstam, Funda
    Yuca, Erkan
    Evans, Kurt W.
    Zhao, Ming
    Maejima, Takanori
    Karibe, Tsuyoshi
    Raso, Maria Gabriela
    Tang, Ximing
    Zheng, Xiaofeng
    Rizvi, Yasmeen Qamar
    Akcakanat, Argun
    Scott, Stephen M.
    Wang, Bailiang
    Byers, Lauren A.
    Tripathy, Debu
    Okajima, Daisuke
    Damodaran, Senthil
    CLINICAL CANCER RESEARCH, 2025, 31 (03) : 573 - 587
  • [9] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
    Bendell, Johanna
    Saleh, Mansoor
    Rose, April A. N.
    Siegel, Peter M.
    Hart, Lowell
    Sirpal, Surendra
    Jones, Suzanne
    Green, Jennifer
    Crowley, Elizabeth
    Simantov, Ronit
    Keler, Tibor
    Davis, Thomas
    Vahdat, Linda
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3619 - +
  • [10] Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
    Forero, A.
    Burris, H., III
    Mita, M.
    Specht, J.
    Weise, A.
    Liu, M. C.
    Modi, S.
    Pusztai, L.
    Kostic, A.
    Yang, J.
    Li, M.
    Hengel, S.
    Miller, K.
    CANCER RESEARCH, 2016, 76
12345